HomeBUSINESS
BUSINESS

As Biosimilars Show Mixed Performances, Lantus Follow-On Is on a Roll
(Jul.13.2018)

By Reiji Anasako

Despite a heated development race underway for biosimilar versions of big-name biologics, follow-on products are not making as smooth a headway as generic counterparts. While biosimilars of eight APIs currently available in Japan have yielded mixed performances, Eli Lilly’s Lantus (recombinant insulin glargine) follow-on appears to be gaining traction, outstripping its originator in the basal insulin market ...
(LOG IN FOR FULL STORY)